NEW YORK — Drug discovery firm IMIDomics said on Tuesday that it has raised $16.5 million in a Series A financing round.
The round was led by DNS Capital and included Bristol Myers Squibb, The Pritzker Organization, and Tao Capital.
IMIDomics, which was founded in Spain but relocated to San Francisco earlier this year, has developed a platform that analyzes clinical and molecular data derived from a biobank of patients with immune-mediated inflammatory diseases, or IMIDs, at Vall d’Hebron University Hospital in Barcelona to generate insights into disease biology.
"Our partnerships with institutions like Vall d’Hebron Hospital, as well as the thousands of patients living with immune-mediated inflammatory diseases who have shared their data and samples over the past 15 years, have given us a uniquely strong foundation for analyzing and discovering new ways to treat these complex diseases," IMIDomics CEO Juan Harrison said in a statement.
"With this new funding, we will be able to build on this foundation to fuel our precision discovery efforts and accelerate technologies that are critical to the further development of new IMID treatments, while expanding our teams in the US and Europe," he added.
In early 2020, IMIDomics partnered with Gossamer Bio to discover and develop treatments for immune-mediated inflammatory diseases including inflammatory bowel disease. A few years before that, it began working with Celgene on new IMID drugs.